Hughes Eric A 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 5, 2025
Insider Transaction Report
Form 4
Hughes Eric A
See "Remarks"
Transactions
- Exercise/Conversion
Ordinary Shares
2025-03-03+24,900→ 24,900 total - Sale
Ordinary Shares
2025-03-03$16.19/sh−19,726$319,275→ 5,174 total - Sale
Ordinary Shares
2025-03-04$15.56/sh−5,174$80,495→ 0 total - Exercise/Conversion
Restricted Share Units
2025-03-03−24,900→ 49,801 total→ Ordinary Shares (24,900 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.86 to $16.53, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.455 to $15.75, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 3, 2023, with 24,900 vested on each of March 3, 2024 and March 3, 2025, 24,900 vesting on March 3, 2026, and 24,901 vesting on March 3, 2027.